ALSP Clinical Trial
Official title:
A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) (The Ignite Study)
Verified date | May 2024 |
Source | Vigil Neuroscience, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, open-label study to assess the safety and tolerability of iluzanebart (also referred to as VGL101) in subjects with documentation of a gene mutation in the CSF1R gene for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and to evaluate the effects of iluzanebart on imaging and biomarkers of disease progression in subjects with ALSP. Participants will receive infusions of iluzanebart approximately every 4 weeks for 1 year. The study includes a 52-week, open-label Core Study, followed by a Long-Term Extension (LTE), which provides subjects who complete the original 52-week study (Core Study) with the option to continue treatment for up to an additional 2 years.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | March 31, 2027 |
Est. primary completion date | July 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Participants who have documentation of a gene mutation in the CSF1R gene - Participants fulfill both (Parts A and B) of the following criteria: 1. The participant has more than 2 findings of clinical signs or symptoms in the following categories: 1. Cognitive impairment or psychiatric problem 2. Pyramidal signs on neurological examination 3. Extrapyramidal signs, such as rigidity. 4. Epilepsy 2. MRI findings consistent with ALSP, specifically, bilateral cerebral white matter lesions with or without thinning of the corpus callosum, on the Screening MRI. - The participant must have a study partner (i.e., caregiver, family member, friend, etc.) who, in the investigator's judgment, has frequent and sufficient contact with the subject so as to be able to provide accurate information about the participant's health and cognitive and functional abilities. The study partner must be willing to sign a study partner ICF. Key Exclusion Criteria: - The participant has any neurological disease that poses a risk to the participant or can produce cognitive, motor, or behavioral impairment similar to ALSP, including, but not limited to, brain tumor, hydrocephalus, Alzheimer's disease, frontotemporal dementia (FTD), ALS, stroke, Huntington disease, multiple sclerosis, Parkinson's disease, and Down syndrome. - Participant with any condition or situation that, in the opinion of the investigator or sponsor medical personnel, may place the subject at significant risk, confound the study results, or interfere significantly with the participant's participation in the study. |
Country | Name | City | State |
---|---|---|---|
France | Investigative Site 10 | Paris | |
Germany | Investigative Site 7 | Leipzig | |
Germany | Investigative Site 9 | Tübingen | |
Netherlands | Investigative Site 8 | Amsterdam | |
United Kingdom | Investigative Site 4 | London | |
United States | Investigative Site 5 | Boston | Massachusetts |
United States | Investigative Site 2 | Englewood | Colorado |
United States | Investigative Site 1 | Jacksonville | Florida |
United States | Investigative Site 6 | Philadelphia | Pennsylvania |
United States | Investigative Site 3 | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Vigil Neuroscience, Inc. |
United States, France, Germany, Netherlands, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Core Study Adverse Events | To evaluate the safety and tolerability of iluzanebart for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) by adverse events in the Core Study | Week 24 and Week 52 | |
Primary | Long-Term Extension Adverse Events | To evaluate the safety and tolerability of iluzanebart for the treatment of ALSP by adverse events in the Long-Term Extension | Weeks 52, 76, 100, 124, and 148 | |
Secondary | To evaluate the effects of iluzanebart on volumetric magnetic resonance imaging in participants with ALSP in the Core Study | Change from Baseline to Week 24 and Week 52 in volumetric magnetic resonance imaging (MRI). The unit of this measure is ml. | Week 24 and Week 52 | |
Secondary | To evaluate the effects of iluzanebart on biomarkers of disease progression in participants with ALSP in the Core Study | Change from Baseline to Week 24 and Week 52 in neurofilament light chain (NfL) in cerebrospinal fluid (CSF) and blood | Week 24 and Week 52 | |
Secondary | To evaluate the effects of iluzanebart on biomarkers of target engagement in participants with ALSP in the Core Study | Change from Baseline to Week 24 and Week 52 in soluble colony-stimulating factor 1 receptor (sCSF1R) in CSF | Week 24 and Week 52 | |
Secondary | To evaluate the effects of iluzanebart on the ALSP on biomarkers of disease progression and clinical outcomes in patients with ALSP in the Core Study | Correlations of Week 24 and Week 52 biomarker changes and clinical outcomes | Week 24 and Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05020743 -
Natural History Study in Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
|
||
Enrolling by invitation |
NCT04503213 -
A Study to Assess CSF1R-related Leukoencephalopathy After Stem Cell Transplantation
|
||
Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|